July 5, 2018 9:49am

Q2/18 financial results also known as (AKA) earnings is a ‘scorecard’ of public stem, cell, gene therapies and editing, regenerative therapy and a couple of CNS and RNAi companies.

The current LPS (loss per share) standings reflect the universes’ investing status; then add in their cash position for a better snapshot!

By analyzing these comparisons, investors can begin to gauge the financial health versus the scientific opportunity and whether or not it deserves their investment.

 


COMPANY SYMBOL NET INCOME Q2/18 LOSS Q2/18 LPS Q2/18 CASH  RUNWAY
Aduro Biotech, Inc. ADRO          
Alnylam Pharmaceuticals ALNY          
Applied Genetic Technologies AGTC          
Asterias Biotherapeutics AST          
Athersys, Inc. ATHX          
Adverum Biotechnologies, Inc. ADVM          
Audentes Therapeutics BOLD          
AxoGen, Inc. AXGN          
Bellicum Pharmaceuticals, Inc. BLCM          
BioLife Solutions, Inc. BLFS          
BioMarin Pharmaceuticals BMRN          
Biostage, Inc. BSTG          
BioTime, Inc. BTX          
bluebird bio BLUE          
Brainstorm Cell Therapeutics Inc. BCLI          
Caladrius Biosciences. CLBS          
Cellectis SA CLLS          
Cesca Therapeutics, Inc KOOL          
CRISPR Therapeutics CRSP          
Editas Medicine EDIT          
Fate Therapeutics, Inc. FATE          
Global Blood Therapeutics GBT          
Histogenics Corporation HSGX          
Homology Medicine FIXX          
Intellia Therapeutics NTLA          
Intrexon Corporation XON          
Ionis Pharmaceuticals IONS          
Mesoblast Limited MESO          
MiMedx Group, Inc MDXG          
Neuralstem, Inc.  CUR          
Organovo Holdings, Inc. ONVO          
Osiris Therapeutics, Inc. OSIR          
Pluristem Therapeutics, Inc. PSTI          
ReNeuron Group PLC RENE.L          
Regenxbio RGNX          
Sage Therapeutics SAGE          
Sangamo Biosciences, Inc. SGMO          
Solid Biosciences SLDB          
Spark Therapeutics, Inc. ONCE          
Stemline Therapeutics, Inc. STML          
Ultragenyx RARE          
uniQure N.V. QURE          
Verastem, Inc. VSTM          
Vericel Corporation VCEL          
Voyager Therapeutics VYGR